develop
bonsignori
et
al
kwong
p
et
al
show
therapeut
potenti
human
clinic
use
recent
raxibacumab
migon
et
al
made
histori
first
mab
approv
fda
therapi
prophylaxi
infectiousrel
agentin
case
inhal
anthrax
approv
also
import
first
one
base
anim
model
demonstr
efficaci
anoth
mab
zhu
z
et
al
also
made
histori
recent
first
mab
administ
compassion
basi
human
expos
infecti
agent
hev
base
efficaci
vitro
anim
bossart
k
n
et
al
bossart
k
n
et
al
review
human
mab
potenti
therapeut
select
virus
import
public
health
biosecur
along
capabl
caus
pandem
emerg
virus
eg
sarscov
variant
virus
exist
long
time
eg
ifv
also
highlight
recent
develop
field
broadli
neutral
antibodi
bnab
engin
antibodi
domain
ead
bispecif
fusion
protein
continu
great
import
public
health
well
recent
develop
effect
neutral
screen
method
antibodi
isol
techniqu
design
structurebas
antigen
probe
highthroughput
sequenc
technolog
enabl
rapid
identif
character
antivir
mab
number
use
review
antivir
mab
recent
publish
euler
z
et
al
marasco
w
et
al
prabakaran
p
et
al
ye
j
q
et
al
sarscov
surfac
glycoprotein
protein
glycoprotein
mediat
viral
entri
host
cell
compos
two
subunit
involv
bind
cellular
receptor
angiotensin
convert
enzym
wherea
facilit
fusion
viral
hostcel
membran
sever
group
develop
potent
bnab
target
protein
sarscov
alreadi
review
detail
elsewher
coughlin
et
al
du
l
et
al
prabakaran
p
et
al
zhang
et
al
eg
identifi
ebv
transform
method
traggiai
e
et
al
yang
z
et
al
zhu
z
et
al
show
potent
inhibitori
activ
isol
first
second
outbreak
palm
civet
zhu
z
et
al
two
human
mab
deriv
transgen
mice
human
immunoglobulin
gene
effect
postexposur
prophylaxi
anim
model
greenough
c
et
al
phage
display
technolog
also
use
select
effect
mab
protein
includ
ter
meulen
j
et
al
ter
meulen
j
et
al
duan
j
et
al
prabakaran
p
et
al
hwang
w
c
et
al
bound
domain
show
neutral
sarscov
synergist
fashion
neutral
escap
virus
antibodi
known
target
domain
within
amino
acid
mab
block
bind
crystallograph
character
complex
receptor
bind
domain
rbd
domain
precis
identifi
locat
epitop
hwang
w
c
et
al
prabakaran
p
et
al
potent
neutral
repres
isol
first
sar
outbreak
urbani
palm
civet
two
antibodi
also
protect
mice
challeng
urbani
recombin
virus
bear
glycoprotein
final
xray
structur
analys
sarscov
rbd
complex
antibodi
well
li
f
et
al
reveal
common
molecular
mechan
target
bind
well
specif
differ
strain
includ
specif
bind
strain
antibodi
compet
bind
rbd
suggest
mechan
neutral
involv
interfer
interact
antibodi
complex
structur
also
share
similar
mode
rbd
recognit
seen
rbd
complex
structur
neutral
mous
mab
elicit
immun
chemic
inactiv
sar
cov
pak
j
e
et
al
realiz
possibl
reemerg
sarscov
relat
viru
newli
discov
human
coronaviru
van
boheemen
et
al
research
mab
sarscov
still
continu
recent
new
bnab
highli
conserv
heptad
repeat
sarscov
identifi
cocktail
mab
target
differ
conserv
region
protein
shown
effect
neutral
differ
sarscov
clinic
isol
elshabrawi
h
et
al
also
random
mutagenesi
dna
shuffl
follow
bacteri
display
screen
use
gener
number
higheraffin
variant
equilibrium
dissoci
constant
k
low
pm
improv
rel
parent
rani
et
al
interestingli
contrast
bnab
broad
potent
neutral
activ
sarscov
requir
high
level
somat
hypermut
chen
w
et
al
exampl
much
less
somat
mutat
known
bnab
matur
pathway
mab
much
less
complex
bnab
therefor
elicit
quicker
effect
find
whether
germlin
antibodi
antibodi
low
level
somat
hypermut
could
bind
protein
high
affin
phagedisplay
human
cord
bloodderiv
igm
librari
recent
construct
pan
sarscov
rbd
yield
germlinelik
antibodi
two
mutat
v
region
heavi
light
chain
mutat
j
region
purifi
solubl
fab
bound
protein
rbd
ec
nm
neutral
germlinelik
mab
sarscov
could
use
design
effect
vaccin
immunogen
antibodi
base
therapeut
hev
niv
close
relat
emerg
paramyxovirus
capabl
caus
sever
lethal
diseas
anim
human
eaton
b
et
al
current
approv
therapeut
hev
niv
envelop
virus
two
membran
glycoprotein
attach
g
glycoprotein
bind
viru
receptor
fusion
f
glycoprotein
facilit
fusion
viru
host
cell
membran
antibodi
specif
either
f
g
glycoprotein
neutral
viru
antibodi
specif
g
glycoprotein
appear
domin
target
antigen
neutral
antibodi
potent
neutral
human
mab
target
viral
envelop
glycoprotein
g
identifi
use
highli
purifi
oligomer
solubl
hev
g
sg
glycoprotein
antigen
screen
larg
human
phagedisplay
librari
seven
fab
inhibit
variou
degre
cell
fusion
mediat
hev
select
one
fab
exhibit
high
level
crossreact
hev
niv
g
vitro
affin
matur
light
chain
shuffl
zhu
z
et
al
matur
show
significantli
improv
neutral
activ
niv
hev
vitro
respect
convers
immunoglobulin
format
demonstr
except
crossreact
neutral
capabl
vitro
complet
protect
ferret
lethal
nivmedi
diseas
administ
hour
viru
challeng
bossart
k
n
et
al
crystal
structur
g
glycoprotein
complex
bowden
et
al
xu
k
et
al
well
antibodi
clonal
variant
nikolov
b
et
al
submit
reveal
high
level
overlap
mab
epitop
receptor
bind
site
suggest
mimicri
receptor
recognit
major
molecular
mechan
neutral
activ
crossreact
recent
test
african
green
monkey
agm
infect
hev
bossart
k
n
et
al
fourteen
agm
challeng
intratrach
lethal
dose
hev
infus
twice
dose
begin
either
hour
infect
hour
later
hevmedi
diseas
associ
pathogen
process
agm
essenti
mirror
outcom
observ
hev
infect
human
also
pharmacokinet
agm
similar
previous
publish
human
immunoglobulin
halflif
data
nonhuman
primat
importantli
protect
agm
ill
fatal
diseas
administ
follow
lethal
hev
challeng
untreat
control
subject
succumb
diseas
day
post
infect
although
anim
treatment
group
exhibit
neurolog
sign
diseas
start
recov
day
infect
result
demonstr
success
postexposur
vivo
efficaci
hmab
hev
offer
glimps
potenti
impact
hmab
human
diseas
due
deadli
viral
infect
base
high
efficaci
two
anim
model
fulli
human
natur
administ
compassion
basi
four
patient
australia
expos
hev
side
effect
one
patient
receiv
mab
late
coma
littl
mg
die
three
still
healthi
result
show
exhibit
potent
crossreact
neutral
activ
nipah
viru
hendra
viru
could
use
therapi
prophylaxi
diagnosi
research
reagent
aid
develop
vaccin
recent
year
mab
ebov
filovirida
wnv
flavivirida
ifv
orthomyxovirida
receiv
much
attent
potenti
therapeut
prophylaxi
therapi
infect
human
ebov
envelop
glycoprotein
mediat
attach
target
cell
drive
fusion
viral
membran
endosom
membran
target
cell
five
antigen
distinct
ebov
bundibugyo
viru
sudan
viru
reston
viru
forest
viru
zair
viru
caus
hemorrhag
fever
human
andor
nonhuman
primat
sever
protect
mab
map
five
distinct
epitop
ebola
glycoprotein
wilson
j
et
al
antibodi
lee
j
e
et
al
modifi
version
human
recombin
antibodi
shown
protect
mice
lethal
challeng
ebov
anoth
antibodi
isol
bone
marrow
human
survivor
ebov
infect
target
complex
lee
j
e
et
al
neutral
ebov
vitro
protect
lethal
ebov
challeng
rodent
model
monkey
friedrich
b
et
al
structur
basi
differenti
neutral
antibodymedi
neutral
mechan
ebov
well
establish
bale
et
al
shedlock
j
et
al
recent
studi
two
humanmous
chimer
mab
strong
neutral
activ
zair
zebov
exhibit
partial
protect
activ
rhesu
macaqu
model
ebola
hemorrhag
fever
marzi
et
al
anoth
studi
total
mab
ebov
produc
use
tradit
hybridoma
cell
fusion
technolog
character
elisa
use
zebov
vlp
mab
bound
three
distinct
epitop
region
mous
model
show
mab
improv
surviv
rate
high
dose
lethal
challeng
mouseadapt
zebov
qiu
x
et
al
result
shed
light
antibodymedi
neutral
ebov
implic
novel
therapeut
vaccin
strategi
wnv
mosquitoborn
flaviviru
close
relat
human
epidemiccaus
dengu
yellow
fever
japanes
enceph
virus
previous
human
mab
develop
target
viral
envelop
block
infect
cell
ten
differ
strain
wnv
vitro
includ
origin
lineag
ii
strain
isol
oliph
et
al
appear
affin
precis
epitop
import
determin
wnv
neutral
mab
sanchez
et
al
xray
structur
fab
complex
show
mab
engag
residu
posit
four
loop
diii
consensu
neutral
epitop
sequenc
conserv
wnv
distinct
flavivirus
nybakken
g
e
et
al
anoth
human
mab
isol
patient
neutral
wnv
infect
postattach
stage
viral
lifecycl
mab
block
viru
fusion
liposom
vitro
recogn
viru
particl
recombin
e
ectodomain
suggest
epitop
requir
oligomer
e
arrang
present
virion
subvir
particl
svp
analysi
neutral
escap
mutant
identifi
residu
part
epitop
close
flexibl
didii
hing
interfac
found
critic
antibodi
bind
kaufmann
b
et
al
antiwnv
complex
structur
help
analyz
complet
epitop
understand
mechan
viral
fusion
inhibit
wnv
also
antibodymedi
neutral
relat
flavivirus
yellow
fever
japanes
enceph
tickborn
enceph
virus
influenza
mainli
caus
infect
either
influenza
ifva
influenza
b
ifvb
virus
ifva
consid
danger
ifvb
virus
former
capac
mutat
deadli
pandem
strain
although
latter
also
significantli
contribut
annual
influenza
relat
ill
human
ifva
classifi
subtyp
basi
two
main
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
current
subtyp
ifva
virus
circul
worldwid
includ
pandem
swine
influenza
season
highli
virul
avian
influenza
bird
flu
previous
panel
human
mab
combinatori
display
librari
construct
human
igm
memori
b
cell
recent
influenza
vaccine
isol
throsbi
et
al
mab
broad
heterosubtyp
neutral
activ
antigen
divers
influenza
subtyp
potent
mab
panel
protect
mice
given
lethal
challeng
anoth
studi
use
human
nonimmun
antibodi
phagedisplay
librari
pan
ha
ectodomain
ten
mab
select
found
effect
group
influenza
virus
test
includ
sui
j
et
al
crystal
structur
one
mab
bound
suggest
possibl
explan
neutral
block
infect
insert
heavi
chain
conserv
pocket
stem
region
thu
prevent
membran
fusion
interestingli
use
variabl
heavi
chain
gene
similar
mode
antigen
recognit
bind
conserv
epitop
helix
ha
stem
ekiert
c
et
al
anoth
mab
isol
human
memori
b
cell
bind
sever
group
subtyp
includ
ekiert
c
et
al
complex
structur
ha
show
antibodi
bind
epitop
ha
stem
uniqu
closer
viral
membran
compar
group
antibodi
first
mab
antibodi
isol
use
novel
plasma
cell
cultur
method
found
bind
group
group
corti
et
al
complex
crystal
structur
group
group
respect
reveal
quaternari
epitop
use
heavi
light
chain
cdr
also
anoth
antibodi
identifi
phage
librari
discov
bind
ifva
ifvb
dreyfu
c
et
al
mab
target
differ
globular
head
site
also
known
exampl
corti
et
al
whittl
j
r
et
al
target
calcium
bind
site
sialic
acidbid
pocket
respect
abl
neutral
differ
virus
addit
b
cell
epitop
identifi
studi
could
acceler
design
improv
influenza
vaccin
elicit
bnab
well
antibodybas
therapi
treatment
ifv
sever
mab
human
organ
target
mani
virus
hepat
c
viru
hcv
meuleman
p
et
al
saijo
et
al
vaccinia
viru
vacv
meng
x
et
al
also
develop
mani
use
diagnost
test
anim
model
therapeut
could
potenti
clinic
use
case
epidem
outbreak
terror
attack
four
bnab
capabl
neutral
multipl
primari
isol
identifi
first
two
decad
research
antibodi
target
three
site
envelop
glycoprotein
glycan
site
recogn
trkola
et
al
bind
site
recogn
burton
r
et
al
membran
proxim
extern
region
mper
site
recogn
muster
et
al
stiegler
g
et
al
antibodi
exhibit
high
level
somat
mutat
suggest
import
understand
matur
pathway
properti
put
germlin
predecessor
dimitrov
addit
bnab
sever
mab
intermedi
neutral
activ
isol
character
includ
mab
chen
l
et
al
prabakaran
p
et
al
zhang
et
al
corb
mab
darbha
r
et
al
huang
c
c
et
al
huang
c
c
et
al
kwong
p
et
al
xray
structur
analysi
combin
bind
experi
model
studi
mani
mab
show
subtl
differ
antigen
combin
site
recognit
mechan
compar
observ
bnab
crucial
neutral
recent
two
dozen
bnab
isol
patient
use
direct
neutral
screen
individu
b
cell
design
probebas
b
cell
isol
combin
deep
sequenc
bonsignori
et
al
kwong
p
et
al
verkoczi
l
et
al
includ
two
mab
target
identifi
isol
singl
mabproduc
b
cell
antigen
resurfac
specif
structur
conserv
site
initi
receptor
bind
neutral
screen
individu
b
cell
method
also
use
identifi
sever
new
target
conform
quaternari
epitop
target
epitop
site
near
mper
recent
review
elsewher
bonsignori
et
al
kwong
p
et
al
van
gil
j
et
al
also
fluoresc
activ
cell
sort
fac
deep
sequenc
use
identifi
target
famili
bnab
use
resurfac
core
structurebas
design
also
identifi
notabl
mper
specif
antibodi
significantli
less
diverg
germlin
counterpart
bnab
recent
identifi
phage
display
immun
librari
construct
use
antibodi
gene
repertoir
deriv
hiv
patient
whose
serum
antibodi
show
broadli
cross
reactiv
neutral
activ
specif
bind
activ
mper
peptid
zhu
z
et
al
antibodyom
approach
dimitrov
studi
origin
divers
matur
pathway
human
antibodi
neutral
made
possibl
antibodi
sequenc
despit
signific
challeng
due
error
limit
method
involv
prabakaran
p
et
al
analysi
could
also
use
identifi
less
somat
mutat
bnab
andor
antibodi
matur
intermedi
may
use
elucid
mechan
initi
immun
respons
lead
ultim
develop
bnab
recent
germlinelik
lesssomat
mutat
v
gene
human
antibodi
repertoir
healthi
human
find
antibodi
intermedi
correspond
known
bnab
prabakaran
p
et
al
well
acut
infect
patient
identifi
use
sequenc
thu
applic
new
technolog
use
explor
b
cell
ontogeni
clonal
lineag
could
provid
insight
develop
bnab
templat
design
novel
vaccin
immunogen
dimitrov
hayn
b
f
et
al
kwong
p
et
al
engin
antibodi
domain
ead
kda
could
effect
fullsiz
antibodi
particularli
target
imped
recognit
bnab
steric
occlus
conserv
epitop
env
one
strategi
evad
neutral
immun
respons
first
report
human
vh
domainbas
ead
kda
target
steric
restrict
epitop
potent
neutral
genet
divers
isol
vitro
chen
w
et
al
human
mice
harri
goldstein
et
al
unpublish
sever
variabl
domain
camelid
heavi
chain
antibodi
v
h
hs
select
librari
construct
immun
camelid
env
target
strokapp
n
et
al
singl
domain
antibodi
llama
target
nonstructur
protein
nef
bouchet
j
et
al
also
identifi
character
recent
domain
second
domain
igg
heavi
chain
region
use
scaffold
ead
librari
construct
contain
bind
site
partial
bind
site
variou
fc
receptor
neonat
fc
receptor
fc
gamma
receptor
complement
extend
halflif
involv
stabil
effector
function
fullsiz
antibodi
vivo
thu
ead
could
potenti
develop
nanoantibodi
small
size
still
bear
featur
effector
function
fullsiz
igg
exampl
larg
member
phagedisplay
domain
librari
mutat
residu
two
loop
bc
fg
four
residu
yield
sever
binder
highestaffin
binder
specif
recogn
highli
conserv
epitop
overlap
neutral
seven
nine
isol
differ
clade
multistep
pcr
method
allow
precis
replac
loop
fg
human
complementar
determin
region
heavi
chain
cdr
anoth
librari
along
limit
mutagenesi
loop
bc
de
domain
develop
use
gener
ead
phagedisplay
librari
pan
librari
mper
peptid
result
select
binder
neutral
isol
differ
clade
modest
activ
retain
capabl
bind
fcrn
result
indic
bispecificbifunct
engin
antibodi
domain
could
develop
use
domain
base
ead
interact
noncompetit
neutral
epitop
fcrn
could
mimic
function
fullsiz
antibodi
bind
antigen
well
fcrn
recent
human
solubl
monomer
fc
mfc
construct
use
combin
structurebas
ration
protein
design
multipl
screen
strategi
ying
et
al
mfc
highli
solubl
retain
bind
human
fcrn
compar
fc
taken
togeth
domain
base
ead
well
mfc
use
develop
potenti
antivir
therapeut
could
use
fusion
protein
make
novel
type
abbas
therapeut
small
size
long
halfliv
although
success
alreadi
develop
ead
base
human
fibronectin
domain
jacob
et
al
koid
et
al
camelid
v
h
h
deschacht
n
et
al
shark
variabl
new
antigen
receptor
vnar
domain
fennel
b
j
et
al
ead
mfc
offer
uniqu
biophys
properti
biolog
function
could
use
therapeut
applic
despit
major
obstacl
aris
target
heterogen
strategi
evad
antibodi
immun
respons
emerg
virus
effect
human
mab
prophylaxi
treatment
viral
diseas
turn
realiti
recent
exampl
raxibacumab
approv
fda
inhal
anthrax
therapi
use
human
mab
human
postexposur
prophylaxi
promis
potenti
develop
human
therapeut
mab
virus
addit
recent
discoveri
potent
bnab
patient
ead
target
conserv
epitop
steric
occlud
region
highli
potent
bispecif
fusion
protein
base
ead
well
understand
antibodymedi
neutral
mechan
matur
pathway
bnab
could
use
therapeut
applic
andor
provid
insight
vaccin
develop
